Personalized stem cell treatment for Parkinson's uses a patient's own cells to rebuild the brain's dopamine supply, and new 12-month trial data show real, measurable motor improvement. The therapy, called sasineprocel (ANPD001), is still experimental and not approved, but early results are encouraging enough that it is now moving toward larger trials. The treatment comes from Aspen Neuroscience and is being tested in the ASPIRO Phase 1/2a trial. This article explains what the therapy is, what the results actually showed, who might qualify, and the important limits you should weigh before reading too much into the headlines.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What "personalized" stem cell therapy actually means
- What the 12-month results showed
- Who is being studied — and who isn't yet
- Is it approved, and what are the limits?
- How this differs from other stem cell news
- Frequently Asked Questions
What "personalized" stem cell therapy actually means
Sasineprocel is an *autologous* therapy — meaning it is made from your own cells, not a donor's. Doctors reprogram a patient's cells into induced pluripotent stem cells (iPSCs), then coax them into dopaminergic neuron precursors, the early-stage brain cells that produce dopamine. Parkinson's symptoms come largely from the loss of these dopamine-making neurons.
The idea is to transplant fresh precursor cells into the putamen, a movement-control area of the brain, so they mature and restore some of that missing dopamine. Because the cells come from the patient, Aspen Neuroscience reports the approach needs no long-term immunosuppression and no permanent implanted hardware. That is the key contrast with "off-the-shelf" donor cell therapies, which are covered further below.
What the 12-month results showed
The strongest data come from the first eight patients followed for a full year. On the MDS-UPDRS Part III OFF score — a standard measure of motor symptoms when medication has worn off — patients improved by 15.5 points (low dose) and 13.5 points (high dose). Lower scores mean fewer motor symptoms, so these are meaningful drops.
Patients also gained function in daily life. According to data presented at ISSCR 2026, mean "Good ON time" rose by about 2.1 to 2.4 hours per day — roughly two extra hours of good motor function without troublesome side effects. On safety, Aspen reported through 12 months no serious surgical adverse events, no severe graft-induced dyskinesia, and no symptomatic brain hemorrhages or strokes. For a first-in-human brain-transplant study, that early safety signal matters as much as the efficacy numbers.
Who is being studied — and who isn't yet
This trial has strict entry criteria, so it does not reflect everyone with Parkinson's. The ASPIRO trial registry describes a first-in-human study enrolling people aged 50 to 70 with mild-to-moderate disease that still responds to levodopa. That "still responsive to levodopa" detail is important.
It suggests the therapy is aimed at people earlier in their disease course, not those with long-standing, advanced Parkinson's or major non-motor complications. The scale is also small. As of June 30, 2026, Aspen reported 15 patients dosed across four cohorts — among the largest autologous cell-therapy experiences in Parkinson's, yet tiny compared with what regulators require for approval.
📨 Get Free Parkinson's Guides Alerts
Free · No spam · Unsubscribe anytime
Is it approved, and what are the limits?
No. Sasineprocel is not approved and cannot be prescribed as a treatment. The FDA granted it Regenerative Medicine Advanced Therapy (RMAT) designation, which speeds up development and review — it is not a green light for use.
The program is now advancing toward Phase 3. Read the efficacy results with real caution. As ClinicalTrialsArena noted, the data are open-label, uncontrolled, and based on just eight patients, and come from conference presentations rather than peer-reviewed publication. Until a controlled Phase 3 trial reports, treat these numbers as promising signals, not proof.
- Open-label: everyone knew they got the therapy, which can inflate reported benefit.
- Uncontrolled: there was no comparison group receiving a sham procedure.
- Placebo-sensitive: Parkinson's trials are famous for large placebo responses, so early improvement can shrink in rigorous studies.
How this differs from other stem cell news
You may see other Parkinson's stem cell headlines that sound similar but are not the same. Separate *allogeneic*, or "off-the-shelf," products use donor-derived cells rather than your own. Two examples — bemdaneprocel (BlueRock, from embryonic stem cells) and Kyoto/Sumitomo iPSC cells — published positive Phase 1/2 results in Nature in 2025.
Unlike sasineprocel, these donor therapies require immunosuppression to prevent rejection. The practical distinction for patients: autologous therapy avoids anti-rejection drugs but requires manufacturing cells individually, while allogeneic therapy is ready-made but needs immune suppression. Both approaches are still investigational. If you want to follow the personalized approach directly, you can track the study through the official ASPIRO Phase 1/2a trial registry, which lists status, locations, and eligibility.
Frequently Asked Questions
Can I get sasineprocel from my neurologist now?
No. It is investigational and available only through the ASPIRO clinical trial, not as an approved treatment.
Does this therapy cure Parkinson's?
No. Early data show reduced motor symptoms and more good-functioning hours, not a cure, and the results are still preliminary.
Why does using my own cells matter?
Autologous cells lower the risk of immune rejection, so this approach needs no long-term immunosuppressive drugs, unlike donor-cell therapies.
You Might Also Like
- Personalized stem cell treatment for Parkinson’s: New research shows promising clinical results
- Parkinson’s Treatment Search Guide: Questions People Are Asking and Clear Answers
- SB-0110 Shows Promise in Parkinson’s Research With Innovative PKA Targeting Approach